TEMTempus AI Inc

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed PR Newswire AUSTIN, Texas, July 24...

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will...

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.read more...

Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion...

Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal...

The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.

Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holding while analysts see nearly 38% upside. Here's what the chart says.read more...